Discover how a flexible protein can rearrange itself to multitask efficiently, revolutionizing medicine, agriculture, and ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

In the headquarters of a mid-sized pharmaceutical company preparing for its first product launch, a scene once considered ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...

Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Cell culture innovation is crucial for advancing modern medicine, drug discovery, and understanding complex biological systems.

Vesicor Therapeutics, a San Gabriel-based biotech firm developing p53-based cancer treatments, is set to go public through a ...

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -6.02% and 84.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?